{
  "id": "cf7322232dc02448",
  "title": "MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 ( Xervyteg\u00ae ) in Acute GvHD at ASH 2025",
  "description": "20251208T211500Z",
  "content": "",
  "source": "pharmiweb.com",
  "source_url": "https://www.pharmiweb.com/press-release/2025-12-08/maat-pharma-presents-pivotal-ares-phase-3-results-for-maat013-xervyteg-in-acute-gvhd-at-ash-2025",
  "published_at": "20251208T211500Z",
  "fetched_at": "2025-12-09T00:22:19.510482+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "United States",
  "raw_data": {
    "url": "https://www.pharmiweb.com/press-release/2025-12-08/maat-pharma-presents-pivotal-ares-phase-3-results-for-maat013-xervyteg-in-acute-gvhd-at-ash-2025",
    "url_mobile": "",
    "title": "MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 ( Xervyteg\u00ae ) in Acute GvHD at ASH 2025",
    "seendate": "20251208T211500Z",
    "socialimage": "https://cdn.pharmiweb.com/media/1024/1200x448-pwjobs.png",
    "domain": "pharmiweb.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}